Guggenheim initiated coverage of AN2 Therapeutics (ANTX) with a Buy rating and $9 price target Claim 55% Off TipRanks Unlock powerful investing ...
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ANTX:Disclaimer & DisclosureReport an Issue
One new option listing on July 17th
AN2 Therapeutics Holds 2026 Annual Stockholder Meeting
AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference
Argenx makes a drug for myasthenia gravis, an autoimmune disease. Argenx stock has produced triple-digit quarterly earnings…
In a report released yesterday, Anupam Rama from J.P. Morgan maintained a Buy rating on AnaptysBio, with a price target of…
AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas…
19:50 EDT ADiTx Therapeutics trading halted, news pendingClaim 55% Off TipRanksUnlock hedge fund-level data and powerful…
Anthropic growth has a positive readthrough for this stock, Bank of America said.
